The primary measures for assessing clinical remission in patients with CV encompass improvements in clinical manifestations (such as alleviation of skin symptoms, reduced joint pain, and resolution of peripheral neuropathy) as well as normalization of laboratory indices (including decreased serum cryoglobulin levels, lower IgM levels, recovery of serum complement C4, and restoration of hepatic and renal function) (31). The gene discussed is C4A; the disease is peripheral neuropathy.